Fagron SA
- Company typePublic
- Founded1990
- HeadquartersRotterdam, Netherlands
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Fagron SA firmographics
Firmographics- Name
- Fagron SA
- Legal name
- Fagron NV
- Website
- https://fagron.com
- Company type
- Public
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Where Fagron SA is headquartered
LocationHeadquarters
- HQ city
- Rotterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices15 records
Markets served
Fagron SA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Compounding Products: Sale of raw materials, APIs, excipients, and compounding supplies to pharmacies, hospitals, and clinics for use in preparing customized medications
- Compounding Services: Compounding pharmacy services from Fagron's own sterile and non-sterile facilities producing customized medications for patient-specific prescriptions and batch production for healthcare facilities
- 503B Sterile Compounding: Production of high-quality sterile medications through FDA-registered 503B Outsourcing Facility for healthcare facilities across North America
- Nutraceutical Ingredients: Distribution of high-quality nutraceutical raw materials through the acquisition of Pharmavit Europe, expanding into the high-growth nutraceutical ingredients market across EMEA
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | E-commerce platform with 179+ products available for direct purchase |
| Other | Multi-year contract | B2B quotation-based pricing for institutional customers |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels7 records
Fagron SA product offering
Product offeringCore offering
Fagron is a global pharmaceutical compounding company that supplies raw materials, active pharmaceutical ingredients (APIs), excipients, bases, and compounding equipment to pharmacies, hospitals, and clinics through direct B2B sales and its Fagron Shop e-commerce platform. The company also operates FDA-registered 503A and 503B compounding facilities (AnazaoHealth, Fagron Sterile Services US) that produce customized sterile and non-sterile medications for patient-specific prescriptions and batch production.
Product overview
Fagron SA is a global pharmaceutical compounding company offering a comprehensive portfolio of products, services, and technology solutions. The core offering centers on pharmaceutical compounding materials (raw materials, APIs, excipients) through the Fagron Shop e-commerce platform, complemented by proprietary formulation bases (Pentravan®, SyrSpend®) and compounding equipment (FagronLab™). The company operates specialized compounding facilities (503A/503B) under AnazaoHealth and Fagron Sterile Services US brands, while GX Sciences provides genetic testing services (TrichoTest™, pharmacogenomics). Technology offerings include the Fagron Formulary database for prescribers, Fagron Academy for training, and Phusion ERP for pharmacy management. Latin American operations include Infinity Pharma Brazil, Florien (phytoactive products), and Sovitá (vitality products). The portfolio is unified under the mission of personalizing medicine through customized pharmaceutical preparations.
Differentiator
Problem solved
Functional benefit
Brands
- FagronLab: The first global product line of compounding equipment.
- Fagron Genomics
- GX Sciences
- AnazaoHealth
- Fagron Sterile Services US
- Sovitá
- Florien
- Fagron Tech
- Infinity Pharma Brazil
Products and services
- Fagron Shop E-commerce Platform Online e-commerce platform offering over 179 pharmaceutical compounding products including raw materials, APIs, excipients and formulation accessories for pharmacies and healthcare professionals.
- Pentravan® Transdermal base for topical pharmaceutical compounding applications, used by compounding pharmacists to formulate customized topical preparations.
- SyrSpend® Oral Suspending Vehicles Range of oral suspending vehicles for preparing liquid dosage forms, including SF PH4, SF Alka and various kit configurations used by compounding pharmacies.
- DiluCap Product line of excipients that match the right diluent with each active pharmaceutical ingredient (API) in formulations, supporting accurate compounding.
- FagronLab™ Compounding Equipment The first global product line of compounding equipment for pharmaceutical preparations, supplying pharmacies with laboratory and compounding hardware.
- AnazaoHealth Compounding Services Specialty compounding pharmacy focusing on Wellness, Pain Management, and Nuclear Medicine, operating both 503A and 503B FDA-registered facilities in Tampa, FL and Las Vegas, NV.
- PhytoTress Hair Care Solutions Hair care product line with patented TrichoTech™ technology featuring an intelligent phytocomplex that balances the entire hair system (Bulb, Scalp and Shaft).
- Fagron Sterile Services US DEA and FDA-registered 503B Outsourcing Provider producing sterile medications with cGMP compliant operations for Critical Care, Ophthalmics, Pain Management, and Specialty Presentations.
- L.E.T. Gel Sterile topical anesthetic gel consisting of Lidocaine, EPINEPHRINE and Tetracaine, offered in pre-filled ready-to-administer syringes with 150-day expiry dating for hospitals and clinics.
- GX Sciences Genetic Testing Advanced genetic and biomarker testing laboratory offering Nutrigenomic and Pharmacogenomic testing platforms for healthcare providers, with CLIA and COLA accreditation.
- TrichoTest™ Genetic test analyzing 3 polymorphisms within 16 SNPs related to alopecia, using DNA OpenArray technology to provide personalized hair loss treatment recommendations.
- Phusion ERP Platform Innovative online ERP platform by Fagron Tech that integrates all technical, operational, managerial, and financial aspects of compounding pharmacy operations.
- Fagron Academy Video Platform Centralized hub for pharmaceutical compounding courses, medical scientific training, and educational content for healthcare professionals.
- Fagron Formulary Global initiative offering pharmacists and prescribers a broad range of customized formulas linked to indications for which they can be prescribed.
- Mixing PRO Automatic compounding equipment with pre-programmed settings, mixing capacity up to 2000ml, touch-screen interface, and integrated barcode reader for pharmacy compounding operations.
Quantifiable outcome
- 10.3% revenue growth in Q1 2026 to €263.4 million
- +5 more outcomes
Companies that use Fagron SA
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles3 records
Fagron SA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Fagron SA partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Pete PharmacorePete Pharma announced a strategic distribution and commercialization partnership with Fagron, appointing Fagron as the exclusive reseller of its 3D pharmaceutical printing platform across the United States and Canada. The collaboration combines Pete Pharma's M3DIMAKER hardware, software, and delivery systems with Fagron's commercial reach to expand access to automated solid dosage form manufacturing for 503A and 503B compounding pharmacies.
Scale indicators20 records
Recent moves7 records
Expansion highlights6 records
Fagron SA competitors and assessment
Company assessmentBroad incumbents
- Cardinal Health: Cardinal Health is a major US pharmaceutical and medical product distributor operating at scale. Its broad medical and specialty distribution network intersects with Fagron's hospital and pharmacy channel at the procurement and bulk product supply level, making it a broad incumbent comparable for the distribution side of the business.
- Cencora (formerly AmerisourceBergen): Cencora is a top-tier US pharmaceutical distributor with global specialty distribution and consulting services to manufacturers and pharmacies. It overlaps with Fagron's raw material and API distribution to compounding pharmacies at the upstream wholesale layer.
- McKesson Corporation: McKesson is the largest US pharmaceutical distributor with broad offerings including specialty pharmacy, supply chain solutions, and some compounding-adjacent services. While not a pure compounding peer, it competes with Fagron at the wholesale raw materials and finished dosage distribution layer serving hospital and pharmacy customers.
- B. Braun Melsungen: B. Braun is a global medical and pharmaceutical company with its CAPS division directly competing in 503B compounding. Beyond compounding, B. Braun competes with Fagron in compounding supplies and devices for hospitals across Europe and the Americas, operating at a much broader scale as a diversified incumbent.
Emerging players
- Piramal Pharma Solutions: Piramal Pharma Solutions is a global CDMO offering sterile fill-finish and API manufacturing services that overlap with Fagron's broader API and small molecule manufacturing activities. While focused on contract development for large pharma, it represents an adjacent emerging capability comparable to Fagron's vertically integrated pharmaceutical preparation model.
Direct peers
- Olympia Pharmaceuticals: Olympia Pharmaceuticals operates a 503B outsourcing facility and 503A specialty pharmacy producing sterile and non-sterile compounded medications. It directly competes with Fagron's compounding services for hospitals, clinics, and prescribers across therapeutic areas including hormone replacement and ophthalmology.
- Cantrell Drug Company: Cantrell Drug Company is a US FDA-registered 503B outsourcing facility specializing in sterile admixtures and ready-to-administer injectable products for hospitals. It competes with Fagron Sterile Services US in the same batch compounding segment targeting health systems and GPOs.
- QuVa Pharma: QuVa Pharma is a US 503B FDA-registered outsourcing provider of sterile compounded preparations serving hospitals and healthcare systems. It is one of the largest specialty sterile compounders in the US and a direct competitor to Fagron's 503B outsourcing business.
- Central Admixture Pharmacy Services (CAPS): CAPS, a division of B. Braun, is one of the largest FDA-registered 503B sterile compounding outsourcing facilities in the United States. It directly competes with Fagron Sterile Services US and AnazaoHealth for hospital and health system 503B outsourcing contracts, operating a comparable cGMP-compliant batch compounding model.
- STAQ Pharma: STAQ Pharma is a US-based 503B FDA-registered outsourcing facility producing sterile injectable medications for hospitals and healthcare systems. It competes head-to-head with Fagron's Wichita and Las Vegas 503B operations in critical care, ophthalmics, and pain management formulations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Fagron SA social profiles
Digital presenceFagron SA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fagron SA leadership team
Management profileNumber of profiles
Profiles5 records
Fagron SA subsidiaries and ownership
Company hierarchySubsidiaries27 records
Fagron SA funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fagron SA M&A and investment
M&A and investmentM&A26 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fagron SA
What does Fagron SA do?
Fagron is a global pharmaceutical compounding company that supplies raw materials, active pharmaceutical ingredients (APIs), excipients, bases, and compounding equipment to pharmacies, hospitals, and clinics through direct B2B sales and its Fagron Shop e-commerce platform. The company also operates FDA-registered 503A and 503B compounding facilities (AnazaoHealth, Fagron Sterile Services US) that produce customized sterile and non-sterile medications for patient-specific prescriptions and batch production.
Is Fagron SA a public or private company?
Fagron SA is a public company. It is classified as public and is currently operating.
When was Fagron SA founded?
Fagron SA was founded in 1990. It employs 1,001 to 5,000 people.
Where is Fagron SA based?
Fagron SA is headquartered in Rotterdam, Netherlands, in the Europe region.
How does Fagron SA make money?
Four revenue lines are on record. Pharmaceutical Compounding Products are the primary driver. The others are compounding Services, 503B Sterile Compounding and nutraceutical Ingredients.
Who are Fagron SA's main competitors?
Broad incumbents on record are Cardinal Health, Cencora (formerly AmerisourceBergen), McKesson Corporation and B. Braun Melsungen. Piramal Pharma Solutions is listed as an emerging player. Direct peers are Olympia Pharmaceuticals, Cantrell Drug Company, QuVa Pharma, Central Admixture Pharmacy Services (CAPS) and STAQ Pharma.
Does Fagron SA have an API?
No public API is recorded for Fagron SA.